Related by context. All words. (Click for frequent words.) 73 multicentre randomized 73 Randomised 72 multicenter randomized 69 multicenter randomized placebo controlled 69 randomized multicenter 68 Multicenter 68 multicenter randomized double 68 placebo controlled randomized 68 Phase III randomized 67 Placebo controlled 67 multicenter randomized controlled 67 nonrandomized 67 Randomized controlled 66 prospective randomized 66 multicentre randomized double 66 prospective randomized placebo 66 blind randomized 65 randomized 65 multicentre 65 randomized multicentre 65 Placebo Controlled 64 double blinded randomized 64 multicenter prospective 64 prospective randomized controlled 64 Prospective Randomized Trial 64 Multicenter Randomized Double 64 Randomized Evaluation 64 multicentre randomized controlled 63 prospective multicenter 63 prospective randomized multicenter 63 blind randomized placebo 63 masked placebo controlled 63 EURIDIS 63 randomized placebo controlled 63 Randomized Clinical Trial 63 blinded randomized 63 multicenter 62 NSABP B 62 blind randomized controlled 62 randomized blinded 62 multicenter multinational 62 placebo controlled 62 Controlled Trial 62 Phase IIIb 62 Randomized Double Blind Placebo 62 TMC# C# 62 Randomized Double Blind 61 Placebo Controlled Trial 61 randomized double 61 Randomized Placebo Controlled 61 Left Ventricular Dysfunction 61 Controlled Study 61 Study Evaluating 61 randomized multicenter trial 61 Metabolic Efficiency 61 randomized #:# 61 blind multicenter 61 Efficacy 61 randomized controlled 61 unfractionated heparin UFH 61 ROCKET AF 60 randomized clinical 60 placebo controlled clinical 60 Trial Evaluating 60 Pooled Analysis 60 Prospective Randomized 60 prospective multicenter randomized 60 Randomized Controlled Trial 60 label multicenter 60 multicenter placebo controlled 60 Randomized Double blind 60 Randomized Study 60 Double Blind Placebo 60 double blinded placebo 60 Stent Restenosis 59 Thrombolysis 59 TAXUS ATLAS 59 Double Blind Randomized 59 prospective multicentre 59 Randomized Controlled 59 Acute Ischemic Stroke 59 Subgroup Analysis 59 Randomized Phase II 59 RE LY 59 Oral Fingolimod 59 controlled multicenter 59 blinded placebo controlled 59 double blind placebo 59 randomized controlled clinical 59 Randomized Phase 59 phase IIIb 59 label multicenter Phase 59 prospective observational 59 trials RCTs 59 prospectively randomized 59 Relapsing Multiple Sclerosis 59 Patency 59 multicenter clinical 58 randomized Phase III 58 Long Lesion 58 Initiated Phase 58 Safety Tolerability 58 landmark ATHENA 58 multicenter randomized clinical 58 prospective nonrandomized 58 ASTEROID 58 Sipuleucel T 58 Myocardial Infarction Study 58 Randomized Trial 58 Placebo Controlled Study 58 Monotherapy 58 Pivotal Trial 58 multicenter phase 58 Raloxifene Evaluation MORE 58 randomized crossover 58 Multicenter Phase 58 Acute Myocardial Infarction 58 RAVEL 58 Carotid Revascularization Endarterectomy vs. 58 Carotid 58 placebo controlled Phase III 58 Ranolazine 58 Pharmacokinetic Study 58 randomization 57 Intervention Trial 57 Prospective Multicenter 57 TRANSFORMS 57 #:# randomization 57 Carotid Endarterectomy 57 Clinical Evaluation 57 Multicentre 57 cluster randomized controlled 57 blind placebo 57 Clinical Outcome 57 blinded placebo 57 comparing XIENCE V 57 Intervention Effectiveness 57 Adjuvant Therapy 57 Long Term Efficacy 57 Refractory Angina 57 MADIT II 57 multicentre prospective 57 randomized placebo 57 PRECISE 57 FREEDOMS 57 Neoadjuvant 57 Randomized Phase III 57 Tolerability 57 Eluting 57 Autologous Stem Cell Transplantation 57 nab paclitaxel 57 II Clinical Trial 57 randomized blinded placebo 57 Clinical Efficacy 57 randomized controlled trial 57 BRIM2 57 Infarct 57 Edge STudy 57 ASSERT 57 Phase 2b Study 57 ACTIVE W 57 Sorafenib HCC Assessment 56 Clinical Trial Evaluating 56 multinational multicenter randomized 56 dose escalation clinical 56 fosbretabulin 56 PRoFESS 56 Myocardial Infarction 56 Bivalirudin 56 ascending dose 56 Unfractionated Heparin 56 Aggressive Drug Evaluation 56 Tiotropium 56 Glatiramer Acetate 56 BR.# 56 pharmacokinetics PK 56 Pharmacokinetic 56 Cyclophosphamide 56 Abciximab 56 Occlusion 56 Stenting 56 Multicenter Study 56 ritonavir boosted 56 Phase III randomized placebo 56 Observational Study 56 Pulmonary Arterial Hypertension 56 Peginterferon 56 label multicenter randomized 56 Pegylated Liposomal Doxorubicin 56 placebo controlled Phase 56 multicenter Phase III 56 ACCOMPLISH 56 HCV SPRINT 56 HALTS 56 PROTEGE 56 stage IIIB 56 RADIANT 56 Left Ventricular 56 Metastatic Prostate Cancer 56 RECORD1 56 IMPACT DCM 56 Percutaneous Coronary Intervention 56 Clinical Trial Results 56 blind multicentre 56 Phase III Clinical Trial 55 Immunosuppression 55 ADMIRE HF 55 recurrent glioblastoma multiforme 55 Intravascular 55 rFVIIa 55 Endarterectomy 55 Clinical Antipsychotic Trials 55 Meta Analysis 55 Intracranial Aneurysms 55 randomized #:#:# 55 randomized controlled multicenter 55 Phase III Trial 55 COPERNICUS 55 Stenting Trial CREST 55 ExTRACT TIMI 55 NO# [002] 55 Multicenter Randomized 55 pegylated interferon alfa 2b 55 Multicenter Trial 55 DEFER 55 registrational Phase 55 Intervention Effectiveness CATIE 55 evaluating carfilzomib 55 Patients Treated 55 Treatment Naive 55 NEVO RES 55 Multiple Ascending Dose 55 PREVAIL 55 CHARISMA 55 Randomized Comparison 55 CARE HF 55 GISSI 55 Sirolimus Eluting Stent 55 active comparator 55 subanalysis 55 viral kinetics 55 Solid Tumors 55 Nilotinib 55 Prostate AdenoCarcinoma Treatment 55 Phase IIB 55 RE MODEL 55 Blind Placebo Controlled 55 Phase III randomized controlled 55 Eluting Stent 55 subgroup analyzes 55 ECASS 55 Patients Undergoing 55 Fondaparinux 55 PEG IFN 55 Well Tolerated 55 Sirolimus eluting 55 Val HeFT 55 randomized controlled clinical trials 55 Pharmacokinetics 54 Antihypertensive 54 blinded randomized placebo controlled 54 Novel Oral 54 Pemetrexed 54 Bare Metal Stent 54 Adalimumab 54 Carotid Stenting 54 Chronic Hepatitis C 54 Fixed Dose 54 Pivotal Phase 54 Pharmacodynamics 54 Unstable Angina 54 MIVI III 54 efavirenz EFV 54 Severe Sepsis 54 CAMMS# 54 RE LY ® 54 Adjuvant Chemotherapy 54 EVEREST II 54 CUSTOM II 54 Risk Stratification 54 Relapsing Remitting Multiple Sclerosis 54 Ranibizumab 54 Initiate Phase 54 Metastatic Colorectal Cancer 54 phase IIb clinical 54 Pharmacokinetics PK 54 Hepatocellular Carcinoma 54 Valsartan 54 DAPT 54 BRIM3 54 Peginterferon Alfa 2a 54 Deforolimus 54 Blind Placebo Controlled Trial 54 SPIRIT FIRST 54 BCIRG 54 By JENNIFER LEARN 54 Antiviral Therapy 54 Heart Failure Patients 54 Catheter Ablation 54 sorafenib Nexavar 54 Sustained Efficacy 54 Trandolapril 54 ISAR REACT 54 Stent Thrombosis 54 Dual Antiplatelet Therapy 54 Pivotal Phase III 54 Efficacy Trial 54 dose dose escalation 54 TROPIC 54 ONTARGET 54 IV NSCLC 54 noninferiority 54 Radiofrequency Ablation 54 Adenoma Prevention 54 NCT# ClinicalTrials.gov 54 APTIVUS 54 Tocilizumab 54 dose escalation 54 sirolimus eluting 54 Randomized phase 54 Bortezomib 54 Aggressive Reduction 54 placebo controlled studies 54 Randomized Controlled Trials 54 Pharmacodynamic 54 Hemodialysis Patients 54 randomized controlled Phase 54 Recurrent Glioblastoma 54 sirolimus eluting stent 54 CLARITY TIMI 54 HCV RESPOND 2 54 ABCSG 54 Renal Cell Carcinoma 54 UNLOAD 54 Antiviral Activity 53 relapsed MM 53 VICTOR E1 53 Echocardiographic 53 icatibant 53 LUX Lung 53 Biphasic 53 GOUT 53 Ischemic Stroke 53 Asthma Intervention 53 Phase III multicenter 53 Sentinel Lymph Node 53 PREVENT IV 53 Elderly Patients 53 Peginterferon Alfa 2b 53 multicenter Phase II 53 Percutaneous Tibial Nerve Stimulation 53 randomized Phase 2b 53 Remission Maintenance 53 Prognostic Significance 53 Free Survival PFS 53 PRE SURGE 53 Vertebroplasty 53 SPIRIT III 53 randomized discontinuation 53 Acute Coronary Syndromes 53 tolerability pharmacokinetics 53 JAK Inhibitor 53 Insulin Glargine 53 ENDEAVOR IV 53 Adjuvant 53 evaluating Vectibix 53 Hormone Refractory Prostate Cancer 53 Spine Patient Outcomes 53 randomized Phase IIb 53 CATIE AD 53 Phase IIIb clinical 53 mg BID 53 Clinical Outcomes Utilizing Revascularization 53 Phase Ib clinical 53 Immunogenicity 53 Tumor Response 53 STENT 53 everolimus eluting stents 53 TRITON TIMI 53 Phase IIb Trial 53 Angiographic 53 Platelet Inhibition 53 Intracranial 53 pharmacokinetic PK 53 controlled multicenter Phase 53 See CLINICAL PHARMACOLOGY 53 Meets Primary Endpoint 53 primary hypercholesterolemia 53 randomized trials 53 sirolimus eluting stents 53 galiximab 53 Radical Prostatectomy 53 Dose Escalation Study 53 Clopidogrel 53 CONQUER 53 Randomized Trials 53 placebo controlled multicenter 53 Plus Ribavirin 53 Prevent Stroke 53 Pegylated Interferon 53 Lipid Lowering Treatment 53 Rosuvastatin 53 Novel Inhibitor 53 Neovascular AMD 53 substudy 53 randomized multicenter Phase III 53 Aneurysm Repair 53 Enoxaparin 53 CALERIE 53 CURRENT OASIS 7 53 Coronary Artery Bypass Graft 53 dose escalation trial 53 Dose Escalation 53 Orally Active 53 randomisation 53 Endovascular Valve Edge 53 Dose Ranging Study 53 Phase IIA 53 Corticosteroid 53 Sequenced Treatment Alternatives 53 Brain Metastases 53 Safinamide 53 Prolongs Survival 53 MATCHED 53 CYPHER ® Sirolimus eluting 53 Patients Treated With 53 prospective observational cohort 53 Epoetin Alfa 53 STRIDE PD 53 pharmacodynamics PD 53 Cardiotoxicity 53 dose escalation Phase 53 Prostate Cancer Prevention 53 Ischemic 53 Pioglitazone 53 Dose Response 53 Ischaemic 53 label dose titration 53 Overactive Bladder 53 relapsed myeloma 53 phase IIa 53 Surgical Treatment 53 Stenting Trial 53 melphalan prednisone 53 Drug Eluting Stents 53 Relieve Depression 53 Adjuvant Treatment 53 Polyp Prevention Trial 53 number NCT# ClinicalTrials.gov 53 Non Responders 53 zonisamide SR 53 REALITY Trial 53 Phase Ib II 53 Pharmacokinetic PK 53 Postmenopausal Women 53 Partial Onset Seizures 53 ATTRACT 53 Lesion 53 metastatic HRPC 52 Chronic Heart Failure 52 Degarelix 52 Tolvaptan 52 Neuroprotective Effects 52 Versus Placebo 52 Tanespimycin 52 Primary endpoints 52 rosuvastatin 52 blind randomized multicenter 52 Arimidex Tamoxifen Alone 52 V Everolimus Eluting Coronary 52 PREZISTA r 52 Glucosamine Chondroitin Arthritis 52 CLL8 52 CABERNET 52 Intravitreal 52 Lung Cancer Trial 52 Severe Asthma 52 Decitabine 52 label dose escalation 52 Ziprasidone 52 dose regimens 52 ERATO 52 ongoing Phase 1b 52 dose escalation phase 52 Pivotal Study 52 AIR CF2 52 Statistically Significant 52 rt PA 52 ARBITER 6 52 Venous Thromboembolism 52 satraplatin Phase 52 Previously Treated 52 AVOREN 52 Anti Tumor Activity 52 lopinavir r 52 CLARITY study 52 ZYBRESTAT fosbretabulin 52 randomized clinical trials 52 post hoc 52 Phase IIb III 52 dosage regimens 52 Hypertensive Patients 52 bosentan 52 Non Inferiority 52 Metastatic Renal Cell Carcinoma 52 phase IIb 52 Naive Patients 52 Anti VEGF 52 TAXUS V 52 Phase III placebo controlled 52 mg/m2 dose 52 Embolization 52 randomized controlled trials 52 Taxotere ® 52 Clinical Trial 52 Decompensated Heart Failure 52 Antitumor Activity 52 RRMS patients 52 Cardiac Resynchronization Therapy 52 sunitinib malate 52 ACCORD Lipid 52 neoadjuvant 52 LUMINATE 52 Nebulized 52 ENESTnd 52 Fludarabine 52 Renal Artery 52 phase IIa clinical 52 Relapsed Multiple Myeloma 52 aspirin clopidogrel 52 observational cohort 52 CCX# B 52 CABANA 52 Telmisartan 52 Targeted Therapy 52 BARI 2D 52 Lacosamide 52 ID NCT# 52 Patients Receiving 52 Phase 1b clinical 52 antiretroviral naive 52 IN PATIENTS WITH 52 ascending dose study 52 placebo controlled trials 52 BOLDER II 52 RE SURGE 52 VADT 52 Newly Diagnosed Multiple Myeloma 52 Adjunctive 52 Dasatinib 52 viral kinetic 52 multicenter study 52 pegylated liposomal doxorubicin 52 PRECiSE 52 Phase 2a Clinical Trial 52 Investigational Drug 52 AIR CF1 52 Regimens 52 Protease Inhibitors 52 pharmacodynamic profiles 52 Multicenter Automatic Defibrillator Implantation 52 Cardiac Allograft Rejection 52 CELLO 52 Treatment Naive HIV 52 Stent Implantation 52 POISE 52 Demonstrates Efficacy 52 CHAMPION PCI 52 ritonavir boosted lopinavir 52 blind placebo controlled 52 ENVISION 52 certolizumab 52 Doxil ® 52 Watchful Waiting 52 MEND CABG 52 Paclitaxel Eluting 52 Demonstrates Positive 52 SCH # 52 Phase IIIb study 52 Antiplatelet 52 unblinded 52 dosing regimens 52 Subcutaneous 52 Sibutramine Cardiovascular Outcomes 52 Refractory Hodgkin Lymphoma 52 CALGB # [002] 52 lacosamide 52 THAT ARE DIFFICULT TO 52 MEND CABG II 52 ACCLAIM 51 ISAR TEST 51 Coronary Angiography 51 adalimumab 51 Kidney Transplantation 51 multicentric 51 ILLUSTRATE 51 eptifibatide 51 MADIT 51 Treatment Outcome 51 Non Alcoholic Steatohepatitis 51 ENDEAVOR 51 relapsing multiple sclerosis 51 Desvenlafaxine Succinate 51 Long Term Outcomes 51 Survival Benefit 51 Antiplatelet Therapy 51 TIMI 51 Clinical Relevance 51 mRCC 51 Liraglutide Effect 51 Evaluation WISE 51 non inferiority 51 AVERROES 51 TO AVOID PREGNANCY WHILE 51 EORTC 51 longitudinal cohort study 51 subcutaneously administered 51 daily Infergen 51 Interferon Alfa 51 Phase 2b randomized 51 Meta analyzes 51 Hepatic Encephalopathy 51 Improves Survival 51 Stereotactic Radiosurgery 51 HYVET 51 prospectively defined 51 Diabetic Nephropathy 51 BOLDER 51 Cardiovascular Events 51 Phase 2b Clinical Trial 51 Infarction 51 bevacizumab Avastin R 51 Aflibercept 51 Renal Function 51 Enzastaurin 51 SORT OUT 51 prospective multicenter study 51 Drug Eluting 51 XIENCE V PROMUS Stent 51 Metastatic Melanoma 51 Phase III VISTA 51 Pivotal Trials 51 Localized Prostate Cancer 51 vs. Angiography 51 Induction Therapy 51 Phase 2b kidney transplant 51 acute peripheral arterial 51 phase Ib 51 ritonavir boosted atazanavir 51 Celecoxib APC trial 51 Improves Outcomes 51 Cardiovascular Risk 51 saline placebo 51 Prostate Lung Colorectal 51 Acute Decompensated Heart Failure 51 Mechanistic 51 adjunctive placebo 51 Phase III Clinical Trials 51 Molecular Weight Heparin 51 Advanced Melanoma 51 Denufosol 51 Appears Safe 51 LEXIVA r 51 ancrod 51 Kaplan Meier analysis 51 Diabetic Foot Ulcer 51 Scandinavian Simvastatin Survival 51 Castration Resistant Prostate Cancer 51 Invasive Breast Cancer 51 Bosentan 51 F FDG PET 51 4mg/kg 51 Statin Therapy 51 ATACAND 51 RADIATE 51 Prophylaxis 51 colesevelam HCl 51 Treatment Resistant 51 Non inferiority 51 Nucleoside 51 Restenosis 51 Myocardial Ischemia 51 prostate cancer mCRPC 51 SANTE 51 Infliximab 51 Truvada tablets 51 TAXUS IV 51 EmbraceAC 51 alfa 2a 51 ABVD 51 DA VINCI 51 Methylnaltrexone 51 Bevacizumab 51 acute PAO 51 divalproex sodium 51 CHARM Added 51 Microplasmin 51 male Wistar rats 51 demonstrated clinically meaningful 51 REALISM 51 Induction Chemotherapy 51 Pharmacologic 51 pharmacokinetic pharmacodynamic PK PD 51 vitreous hemorrhage 51 METHOD 51 Cardiac Resynchronization 51 virologic response 51 NATRECOR ® 51 #mg QD [002] 51 Clinical Study 51 dose titration 51 Multivessel Evaluation 51 insulin detemir 51 EGFR HER2 51 XIENCE TM 51 MOTIVATE 51 NOXAFIL Oral Suspension 51 ANDROMEDA 51 CANCIDAS 51 mCi kg 51 valsartan 51 abacavir Ziagen 51 Infected Patients 51 recurrent GBM 51 Abatacept 51 tenofovir emtricitabine 51 Treated Patients 51 5 fluorouracil leucovorin 51 NAVISTAR R 51 Randomised Trial 51 Pharmacological 51 Events MACE 51 ADAGIO 51 Medidur TM FA 51 alpha 2a 51 carotid artery stenting CAS 51 Tipranavir 51 ST Segment Elevation 51 evaluating satraplatin plus 51 PHASE III 51 prospectively stratified 51 ADONIS 51 Inflammatory Pain 51 oral rivaroxaban 51 AIM HIGH 51 Natalizumab 51 Diabetic Patients 51 Omacetaxine mepesuccinate 51 metastatic malignant 51 pimecrolimus cream 51 Capecitabine 51 TMC# r 51 EINSTEIN DVT 51 ALLEGRO 51 SABCS 51 Investigational Agent 51 carboplatin paclitaxel 51 Aplidin R 51 FEMALES SHOULD BE ADVISED 51 Eculizumab 50 OLYMPIA registry 50 #F FDG PET 50 CIMZIA R 50 MIST II 50 moderate hepatic impairment 50 familial amyloidotic polyneuropathy FAP 50 Randomized trials 50 Protease Inhibitor 50 TM Drug Eluting 50 Endovascular Treatment 50 FOLPI 50 Xelox 50 fluvastatin 50 glatiramer acetate 50 cinacalcet 50 designated HVTN 50 CALGB 50 Rheumatoid Arthritis Patients 50 Bone Metastases 50 Demonstrates Potent 50 dasatinib Sprycel ® 50 everolimus eluting stent 50 hydroxymethyl coenzyme 50 erlotinib Tarceva ® 50 Phase IIb randomized 50 Chronic Renal Failure 50 Total Knee Arthroplasty 50 Percutaneous 50 Melphalan 50 Complicated Skin 50 Patient Outcomes 50 rosuvastatin #mg 50 Phase III psoriasis 50 EXPAREL ™ 50 prucalopride 50 Prostate Biopsy 50 Sandostatin R 50 ARB telmisartan 50 prospective cohort 50 Phase III Pivotal 50 randomized controlled trials RCTs 50 Unresectable 50 weekly subcutaneous injections 50 plus prednisone 50 MGd 50 Traficet EN 50 Combination Treatment 50 Low Dose 50 IMPACT IMmunotherapy 50 Mycophenolate Mofetil 50 Intravesical 50 SORT OUT III 50 Coronary Revascularization 50 candesartan cilexetil 50 Fracture Intervention Trial 50 IIIa inhibitor 50 liposome injection 50 temsirolimus 50 confirmatory Phase III 50 Observational Studies 50 J Am Coll 50 Radiofrequency Ablation RFA 50 Histopathological 50 Attenuates 50 GnRH agonist 50 APTIVUS r 50 radical cystectomy 50 Antipsychotic 50 Cholesterol Levels SPARCL 50 3TC lamivudine Epivir 50 olmesartan 50 multicenter Phase 50 Study Showed 50 epoetin alpha 50 Combination REOLYSIN R 50 MELD scores 50 Completes Enrollment 50 Phase III confirmatory 50 Aortic Valve 50 superficial bladder cancer 50 FOLFIRI 50 RIBBON 50 Systematic Review 50 Thyroid Hormone 50 dacarbazine 50 Atherosclerotic 50 FIX HF 5 50 Combination Therapy 50 metastatic renal cell carcinoma 50 Completes Patient Enrollment 50 Allogeneic 50 PERSEUS 50 cells mcL 50 pharmacodynamic PD 50 GISSI HF 50 APPRAISE 50 ENGAGE AF TIMI 50 Molecular Basis 50 FOLFOX 50 Monitoring ABPM 50 MERLIN TIMI 50 Endovascular Repair 50 Anticancer Activity 50 Zoledronic Acid 50 SYNTAX 50 Meta Analyses 50 Antiretroviral Therapy 50 ORACLE MS 50 postmenopausal osteoporotic women 50 Gemcitabine 50 Preclinical Data 50 EXPLORE Xa 50 Ovarian Cancer Screening 50 posaconazole 50 placebo controlled dose escalation 50 IL# PE#QQR 50 REVIVE 50 Lipid Lowering 50 adenoma recurrence 50 Estrogen Receptor 50 QD dosing 50 Darunavir 50 ribavirin RBV 50 dosing schedules 50 VICTOR E3 50 chemoradiation therapy 50 darunavir ritonavir 50 #F FDG PET CT 50 Phase Ib Clinical Trial 50 HCV Genotype 50 EuroIntervention 50 Randomized Placebo Controlled Trial 50 Sirolimus Eluting 50 Vertebral Fracture 50 Relapsed 50 Immunomodulatory 50 IIa clinical 50 Initiate Phase II 50 fallopian tube cancers 50 KRN# 50 Lenalidomide 50 paclitaxel poliglumex 50 Percutaneous Transluminal Coronary Angioplasty 50 TAXUS VI 50 HF ACTION 50 composite endpoint 50 Preclinical Models 50 Sprague Dawley rats 50 Pegasys ® 50 Diabetic Neuropathy 50 Sustained Virologic Response 50 phase IIb III 50 aflibercept VEGF Trap 50 Bare Metal Stents 50 Adverse Event 50 Spectrum Pharmaceuticals Announces 50 CORD II 50 Phase IIb Clinical Trial 50 SIMPADICO 50 invasive candidiasis 50 atherosclerotic renal artery stenosis 50 J Am Soc 50 neurologic progression 50 bevacizumab Avastin 50 Postmarketing 50 Kidney Transplant Recipients 50 NCIC CTG 50 Etanercept 50 CONQUER OB 50 CIMZIA TM certolizumab pegol 50 SPIRIT IV 50 Antiangiogenic 50 meta analyzes 50 Antiepileptic Drug 50 Shows Efficacy 50 STICH trial 50 fondaparinux 50 ALLHAT 50 Glycemic Control 50 TG MV 50 doxorubicin docetaxel 50 AIR2 Trial 50 NSTE ACS 50 liposomal doxorubicin 50 Oral Anticoagulant 50 refractory prostate cancer 50 Kidney Function 50 Adefovir 50 assessing T DM1 50 pegaptanib 50 Preclinical Study 50 5 Fluorouracil 50 PROVENGE ® 50 chemoradiotherapy 50 REYATAZ r 50 Relapsed Refractory 50 National Emphysema Treatment 50 Autologous 50 comparing alemtuzumab 50 fluorouracil 49 Potent Inhibitor 49 NCCTG N# 49 Phase III Psoriasis 49 tirofiban 49 eluting stent 49 Dosed 49 Clostridium difficile Infection 49 coadministration 49 Phase 2b clinical 49 evaluating tivozanib 49 Cost Effectiveness 49 Late Breaker 49 HER2 Positive Breast Cancer 49 R# #mg BID 49 IFN alfa 49 PHASE II 49 Knee Osteoarthritis 49 Hepatitis C Antiviral 49 BEACOPP 49 Cardiac Function 49 Sapacitabine 49 abacavir lamivudine 49 interferon gamma 1b 49 CAPRIE 49 PEGylated interferon beta 1a 49 REVLIMID lenalidomide 49 PREZISTA ritonavir 49 induced macular edema 49 ENDEAVOR II 49 Efficacy Study 49 Septic Shock 49 Dexamethasone 49 Rivaroxaban 49 Amrubicin 49 pharmacodynamics 49 Metastatic Pancreatic Cancer 49 Universal Flu Vaccine 49 paclitaxel carboplatin 49 Lung Tumors